Phase 1/2a Safety and Immunogenicity of an Adenovirus 26 Vector Respiratory Syncytial Virus (RSV) Vaccine Encoding Prefusion F in Adults 18-50 Years and RSV-Seropositive Children 12-24 Months.

Autor: Stuart ASV; Oxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, United Kingdom., Virta M; Tampere University, Tampere, Finland., Williams K; Janssen Vaccines & Prevention BV, Leiden, The Netherlands., Seppa I; Tampere University, Tampere, Finland., Hartvickson R; Axtell Clinic, Newton, Kansas, USA., Greenland M; Oxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, United Kingdom., Omoruyi E; Janssen Infectious Diseases, Beerse, Belgium., Bastian AR; Janssen Vaccines & Prevention BV, Leiden, The Netherlands., Haazen W; Janssen Vaccines & Prevention BV, Leiden, The Netherlands., Salisch N; Janssen Vaccines & Prevention BV, Leiden, The Netherlands., Gymnopoulou E; Janssen Infectious Diseases, Beerse, Belgium., Callendret B; Janssen Vaccines & Prevention BV, Leiden, The Netherlands., Faust SN; NIHR Southampton Clinical Research Facility and NIHR Biomedical Research Centre, University Hospital Southampton NHS Foundation Trust, Southampton, United Kingdom.; Faculty of Medicine and Institute for Life Sciences, University of Southampton, Southampton, United Kingdom., Snape MD; Oxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, United Kingdom.; Oxford NIHR - Biomedical Research Centre, Oxford University Hospitals NHS Foundation Trust, Oxford, United Kingdom., Heijnen E; Janssen Vaccines & Prevention BV, Leiden, The Netherlands.

Publikováno v: The Journal of infectious diseases [J Infect Dis] 2022 Dec 28; Vol. 227 (1), pp. 71-82.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Non-inferiority of mammalian cell-derived quadrivalent subunit influenza virus vaccines compared to trivalent subunit influenza virus vaccines in healthy children: a phase III randomized, multicenter, double-blind clinical trial.

Autor: Hartvickson R; Heartland Research Associates, LLC, Newton, Kansas, USA., Cruz M; Premier Health Research Center, LLC, Downey, California, USA., Ervin J; The Center for Pharmaceutical Research, Kansas City, Missouri, USA., Brandon D; California Research Foundation, San Diego, California, USA., Forleo-Neto E; Novartis Vaccines and Diagnostics Inc., Cambridge, Massachusetts, USA., Dagnew AF; Novartis Vaccines and Diagnostics Inc., Cambridge, Massachusetts, USA., Chandra R; Novartis Vaccines and Diagnostics Inc., Cambridge, Massachusetts, USA., Lindert K; Novartis Vaccines and Diagnostics Inc., Cambridge, Massachusetts, USA., Mateen AA; Novartis Pharmaceuticals Canada Inc., 385 Bouchard Blvd, Dorval, Quebec, H9S 1A9, Canada. Electronic address: ahmed.abdul_mateen@novartis.com.

Publikováno v: International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases [Int J Infect Dis] 2015 Dec; Vol. 41, pp. 65-72. Date of Electronic Publication: 2015 Nov 14.

Host Responses to Respiratory Syncytial Virus Infection.

Autor: Agac, Ayse¹ (AUTHOR) ayse.agac@tiho-hannover.de, Kolbe, Sophie M.¹ (AUTHOR), Ludlow, Martin¹ (AUTHOR), Osterhaus, Albert D. M. E.¹ (AUTHOR), Meineke, Robert¹ (AUTHOR), Rimmelzwaan, Guus F.¹ (AUTHOR) guus.rimmelzwaan@tiho-hannover.de

Publikováno v: Viruses (1999-4915). Oct2023, Vol. 15 Issue 10, p1999. 38p.

Age-Stratified Seroprevalence of Respiratory Syncytial Virus: Analysis Using Prefusion F and G Protein Antibodies.

Autor: Nham, Eliel, Jang, A-Yeung, Hyun, Hakjun, Yoon, Jin Gu, Noh, Ji Yun, Cheong, Hee Jin, Kim, Woo Joo, Ahn, Ki Bum, Ji, Hyun Jung, Seo, Ho Seong, Bae, Joon-Yong, Park, Man-Seong, Song, Joon Young

Publikováno v: Vaccines; May2024, Vol. 12 Issue 5, p513, 7p